公开(公告)号：EP1768667B1

公开(公告)日：2009-09-30

申请号：EP05766578.8

申请日：2005-06-21

申请人： Schering Corporation

发明人： SHANKAR, Bandarpalle, B. ,  GILBERT, Eric ,  RIZVI, Razia, K. ,  HUANG, Chunli ,  KOZLOWSKI, Joseph, A. ,  MCCOMBIE, Stuart ,  SHIH, Neng-Yang

IPC分类号： A61K31/438 ,  C07D209/52 ,  C07D221/20 ,  C07D401/12 ,  C07D471/08 ,  A61P29/00

CPC分类号： C07D221/20 ,  C07D209/52 ,  C07D401/12 ,  C07D471/08

摘要： Compounds of Formula (I) and/or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions containing such compounds exhibit anti-inflammatory and immunomodulatory activity, and can be effective asCB2 receptor ligands in treating cancer and inflammatory, immunomodulatory or respiratory diseases or conditions.

公开(公告)号：EP1858886A1

公开(公告)日：2007-11-28

申请号：EP06735563.6

申请日：2006-02-21

申请人： Schering Corporation

发明人： COX, Kathleen ,  MCCOMBIE, Stuart ,  WESTON, Daniel ,  MILLER, Michael W. ,  CHAN, Tze-ming ,  FENG, Wenqing

IPC分类号： C07D401/14 ,  A61K31/4545 ,  A61P31/18

CPC分类号： C07D401/14

摘要： In its many embodiments, the present invention provides a novel class of compounds of structural formula (IA) or (IB) where R1-R8 are as disclosed herein as inhibitors of the CCR5 receptors, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with CCR5 using such compounds or pharmaceutical compositions. The invention also relates to the use of a combination of a compound of this invention and one or more antiviral or other agents useful in the treatment of Human Immunodeficiency Virus (HIV). The invention further relates to the use of a compound of this invention, alone or in combination with another agent, in the treatment of solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis.

公开(公告)号：EP1768667A1

公开(公告)日：2007-04-04

申请号：EP05766578.8

申请日：2005-06-21

申请人： SCHERING CORPORATION

发明人： SHANKAR, Bandarpalle, B. ,  GILBERT, Eric ,  RIZVI, Razia, K. ,  HUANG, Chunli ,  KOZLOWSKI, Joseph, A. ,  MCCOMBIE, Stuart ,  SHIH, Neng-Yang

IPC分类号： A61K31/438 ,  C07D209/52 ,  C07D221/20 ,  C07D401/12 ,  C07D471/08 ,  A61P29/00

CPC分类号： C07D221/20 ,  C07D209/52 ,  C07D401/12 ,  C07D471/08

摘要： Compounds of Formula (I) and/or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions containing such compounds exhibit anti-inflammatory and immunomodulatory activity, and can be effective asCB2 receptor ligands in treating cancer and inflammatory, immunomodulatory or respiratory diseases or conditions.

公开(公告)号：EP1725235B1

公开(公告)日：2009-04-15

申请号：EP05712200.4

申请日：2005-02-02

申请人： Schering Corporation

发明人： TING, Pauline C. ,  CAO, Jianhua ,  DONG, Youhao ,  GILBERT, Eric J. ,  HUANG, Ying ,  KELLY, Joseph M. ,  MCCOMBIE, Stuart ,  SHIH, Neng-Yang

IPC分类号： A61K31/4709 ,  A61K31/444 ,  A61P11/06 ,  C07D401/04 ,  C07D401/14

CPC分类号： C07D401/14 ,  C07D211/18 ,  C07D211/58 ,  C07D401/04 ,  C07D471/04

摘要： The use of CCR3 antagonists of the formula (I) or a pharmaceutically acceptable salt thereof for the treatment of asthma is disclosed, as well as novel compounds of the formula (II), pharmaceutical compositions comprising them, and their use in the treatment of asthma, wherein R, Ra, X, Xa, R1, R2, R2a, R14, R14a, R16 and n are as defined in the specification.

公开(公告)号：EP1725235A1

公开(公告)日：2006-11-29

申请号：EP05712200.4

申请日：2005-02-02

申请人： SCHERING CORPORATION

发明人： TING, Pauline C. ,  CAO, Jianhua ,  DONG, Youhao ,  GILBERT, Eric J. ,  HUANG, Ying ,  KELLY, Joseph M. ,  MCCOMBIE, Stuart ,  SHIH, Neng-Yang

IPC分类号： A61K31/4709 ,  A61K31/444 ,  A61P11/06 ,  C07D401/04 ,  C07D401/14

CPC分类号： C07D401/14 ,  C07D211/18 ,  C07D211/58 ,  C07D401/04 ,  C07D471/04

摘要： The use of CCR3 antagonists of the formula (I) or a pharmaceutically acceptable salt thereof for the treatment of asthma is disclosed, as well as novel compounds of the formula (II), pharmaceutical compositions comprising them, and their use in the treatment of asthma, wherein R, Ra, X, Xa, R1, R2, R2a, R14, R14a, R16 and n are as defined in the specification.